John Newman


Canaccord Cheers Mast Therapeutics Inc (MSTX) In Light Of Strategic Merger With Savara

Mast Therapeutics Inc (NYSEMKT:MSTX) and privately held pharmaceutical firm Savara Inc. have announced the intent to merge to advance a novel pipeline of …

Canaccord Confident on Synergy Pharmaceuticals Inc (SGYP) Following Competitor Phase 3 Linzess CIC Trials Three-Day Treatment Break

Canaccord analyst John Newman is out today with a favorable research report on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) after the firm’s competition, Phase 3 …

Here’s Why Canaccord Sings the Praises of Synergy Pharmaceuticals Inc (SGYP); Shares Rise 5%

After market-close yesterday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released positive second Phase 3 results for plecanatide, the firm’s pipeline daily pill designed to treat …

Canaccord Chimes in on Radius Health Inc (RDUS) Following Promising Phase 1 Data in Breast Cancer

Yesterday, Radius Health Inc (NASDAQ:RDUS) shares rose a solid 6% on back of RAD-1901 Phase 1 study clinical data that proved to be better …

Canaccord Lays Out the Bullish Case for Agios Pharmaceuticals Inc (AGIO) Despite IND Withdrawal

Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were thundering down 19% yesterday after news came to light that the firm has withdrawn its Investigational New …

Canaccord Comments on Synergy Pharmaceuticals Inc (SGYP) Following First Phase 3 Data in IBS-C

In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a $13 price …

Canaccord Chimes In On Agios Pharmaceuticals Inc (AGIO) Following ASH Event

In a research report published Monday, Canaccord analyst John Newman reiterated a Buy rating on shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO), with a …

Canaccord Bullish on Palatin Technologies, Inc. (PTN) Ahead of SSE Data and Partnership Update

Canaccord analyst John Newman speculates on Palatin Technologies, Inc. (NYSEMKT:PTN) ahead of clinical data and partnership updates with a bullish forecast, reiterating a …

Palatin Technologies, Inc. (PTN): Partnership Discussions Likely to Accelerate, Says Canaccord

Palatin Technologies, Inc. (NYSEMKT:PTN) shares jumped 18% today after the company’s key pipeline drug bremelanotide, designed to treat female sexual dysfunction (FSD), hit …

Canaccord Bullish on Celgene Corporation (CELG) on Back of Revlimid Beat

In a research report published Thursday, Canaccord analyst John Newman reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts